Protagonist Therapeutics Inc’s filing revealed that its Chief Financial Officer Ali Asif unloaded Company’s shares for reported $80776.0 on Apr 22 ’25. In the deal valued at $46.00 per share,1,756 shares were sold. As a result of this transaction, Ali Asif now holds 61,065 shares worth roughly $2.72 million.
Then, Waddill William D. sold 4,000 shares, generating $217,000 in total proceeds. Upon selling the shares at $54.25, the Director now owns 13,130 shares.
Before that, WILLIAM D WADDILL bought 4,000 shares. Protagonist Therapeutics Inc shares valued at $219,120 were divested by the Director at a price of $54.78 per share.
Goldman initiated its Protagonist Therapeutics Inc [PTGX] rating to a Neutral in a research note published on December 06, 2024; the price target was $47. A number of analysts have revised their coverage, including BMO Capital Markets’s analysts, who began to cover the stock in early December with a ‘”an Outperform”‘ rating. Wedbush began covering PTGX with “an Outperform” recommendation on November 05, 2024. TD Cowen started covering the stock on September 24, 2024. It rated PTGX as “a Buy”.
Price Performance Review of PTGX
On Friday, Protagonist Therapeutics Inc [NASDAQ:PTGX] saw its stock jump 0.18% to $44.49. Over the last five days, the stock has gained 3.54%. Protagonist Therapeutics Inc shares have risen nearly 15.26% since the year began. Nevertheless, the stocks have risen 50.25% over the past one year. While a 52-week high of $60.60 was reached on 03/12/25, a 52-week low of $27.00 was recorded on 02/25/25. SMA at 50 days reached $47.24, while 200 days put it at $42.97.
Levels Of Support And Resistance For PTGX Stock
The 24-hour chart illustrates a support level at 44.00, which if violated will result in even more drops to 43.51. On the upside, there is a resistance level at 45.09. A further resistance level may holdings at 45.69. The Relative Strength Index (RSI) on the 14-day chart is 49.07, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.09, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 33.71%. Stochastics %K at 60.77% indicates the stock is a holding.
The most recent change occurred on September 09, 2024 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $60 price target.
